These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6867470)

  • 1. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels.
    Powell AC; Elliott SL; Horowitz JD
    Ther Drug Monit; 1988; 10(1):34-8. PubMed ID: 3376179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
    Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE
    Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the plasma protein binding of verapamil and norverapamil in man.
    Yong CL; Kunka RL; Bates TR
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):329-39. PubMed ID: 7444161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentration--response relationship of verapamil in the treatment of angina pectoris.
    Anderson P; Bondesson U; Sylvén C; Aström H
    J Cardiovasc Pharmacol; 1982; 4(4):609-14. PubMed ID: 6181335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    Can J Physiol Pharmacol; 2008 May; 86(5):232-9. PubMed ID: 18432283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
    Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
    Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations.
    Horne C; Spahn H; Mutschler E; Knauf H
    Arzneimittelforschung; 1987 Aug; 37(8):956-9. PubMed ID: 3675692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
    Vlcek J; Macek K; Hůlek P; Brátová M; Fendrich Z
    Arzneimittelforschung; 1995 Feb; 45(2):146-9. PubMed ID: 7710436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs.
    Forrester SD; Wilcke JR; Jacobson JD; Dyer KR
    Am J Vet Res; 1993 Jul; 54(7):1136-8. PubMed ID: 8368611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.